Affymax to create multiple presentations on preclinical and clinical data of Hematide Affymax.

Affymax to create multiple presentations on preclinical and clinical data of Hematide Affymax, Inc. today announced multiple presentations at the American Society of Nephrology Renal Week 2009 occurring October 27 through November 1 in San Diego. Affymax and investigators can make multiple presentations highlighting Hematide preclinical and scientific data in a variety of treatment settings reviews . These include preliminary outcomes of a Phase 2 trial in hemodialysis patients who are not on an erythropoiesis stimulating agent , and interim results from a continuing Phase 2 research in sufferers with antibody-mediated pure red cell aplasia .

‘These results show that lots of patients will have several skin cancer, highlighting the necessity to analyse both individual sample and numbers amounts to provide an accurate picture of cancer levels, says co-writer Dr Susannah Hoey from the Dermatology Department at the Royal Victoria Medical center, area of the Belfast Social and Health Care Trust. ‘The three pores and skin cancers we looked at all improved with age, with the exception of malignant melanomas, which showed a decrease in men aged 75 and over. ‘And there was a link between more patients living in wealthier areas and improved levels of malignant melanomas and basal cell carcinomas.’ The united team viewed data gathered by the Northern Ireland Malignancy Registry, at Queen’s University Belfast, from 1993 to 2004, analysing the records of patients diagnosed with the three most common epidermis cancers.